Lian X.,Zhengzhou University |
Yang G.,Zhengzhou University |
Yang L.,Electrical Hospital of Henan |
Chen Z.,Electrical Hospital of Henan |
And 6 more authors.
Life Science Journal | Year: 2013
Objective To observe the levels of plasma TGF-β1 and PDCD5 in patients with decompensated heart failure and the influence of recombinant human brain natriuretic peptide (rhBNP) treatment on them. Methods 40 patients in NYHA functional classification IV (including 22males, 18 females, aged 65.0±3.7 years) were randomly divided into two groups. 20 patients in rhBNP-treated group received conventional drug such as diuretics, anticoagulation, angiotensin-converting enzyme inhibitor and rhBNP (1.5u g/kg bolus intravenous injection followed by 0.0075mg/kg/min/ intravenous drop infusion for 72 hours). 20 patients in control group received conventional drugs. The levels of plasma TGF-β1 and PDCD5 were determined before and after treatment by enzyme linked immunosorbent assay (ELISA). Results: There were significant differences between TGF-β1 levels among different time points in rhBNP-treated group (Ftime=585.044, P<0.001; Fgroup=40.767, P<0.001). And there were significant differences between PDCD5 levels among different time points in rhBNP-treated group (Ftime=23.615, P<0.001; Fgroup=35.654,P<0.001). Conclusion Long-term treatment with rhBNP decreases the levels of plasma TGF-β1 and PDCD5 persistently. RhBNP may be associated with the prevention of cardiac fibrosis and apoptosis in cardiomyocytes.